Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H29FNO3.Br |
Molecular Weight | 478.394 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=FNUZASGZEHGWQM-XDKPLUGXSA-M
InChI=1S/C24H29FNO3.BrH/c1-26(15-14-25)20-12-13-21(26)17-22(16-20)29-23(27)24(28,18-8-4-2-5-9-18)19-10-6-3-7-11-19;/h2-11,20-22,28H,12-17H2,1H3;1H/q+1;/p-1/t20-,21+,22+,26?;
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6139497Curator's Comment: description was created based on several sources, including:
http://en.pharmacodia.com/web/drug/1_10230.html | https://www.ncbi.nlm.nih.gov/pubmed/7886652 | https://www.ncbi.nlm.nih.gov/pubmed/2431695
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6139497
Curator's Comment: description was created based on several sources, including:
http://en.pharmacodia.com/web/drug/1_10230.html | https://www.ncbi.nlm.nih.gov/pubmed/7886652 | https://www.ncbi.nlm.nih.gov/pubmed/2431695
The anticholinergic agent Flutropium is a classic competitive antagonist of acetylcholine. In in vitro experiments it is more effective than atropine. A poor enteral absorption is to be expected; this can be concluded from the low relative effectiveness after oral administration. After local administration as an aerosol it is superior to atropine with regard to both effectiveness and duration of action. It is used in Japan to treat asthma and chronic obstructive pulmonary disease. Flutropium can be described as a preparation which is free of side effects.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094109 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | FLUBRON Approved UseIt has been used for the relief of symptoms of bronchial asthma and COPD. |
|||
Palliative | FLUBRON Approved UseIt has been used for the relief of symptoms of bronchial asthma and COPD. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7886652
60 ug per puff
Route of Administration:
Respiratory
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29714
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07767MIG
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
C80960
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
m1173
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | Merck Index | ||
|
31630
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
5406
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110646
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
100000080407
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
K3V6HB0M57
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
C039778
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
63516-07-4
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD